The FDA approved a new drug to treat Alzheimer's, but Medicare won't always pay for it – a doctor explains what researchers know about Biogen's Aduhelm
- Written by Andrew Williams, Assistant Professor of Emergency Medicine, Albert Einstein College of Medicine
An illustration of amyloid plaques within the human brain, characteristic features of Alzheimer's. By 2060, approximately 14 million Americans are expected to have the disease.Kateryna Kon/Science Photo Library via Getty ImagesMedicare finalized its decision to restrict its coverage of Aduhelm, Biogen’s new Alzheimer’s disease drug, on...